Please upgrade your browser.
Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife.
Dallas journalist Robert Wilonsky beat the odds with help from the team at UT Southwestern.
Kidney cancer is one of the most common cancers in the U.S. Men are twice as likely as women to be diagnosed with kidney cancer, according to the ACS. Men's increased exposure to cancer-causing chemicals in the workplace and increased likelihood of smoking may partly explain this gap. For all people, though, the symptoms may include blood in the urine, low back pain on one side of the body that's not linked to an injury, a lump in the lower back, fatigue, appetite loss, unexplained weight loss, and more.
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy.
CIP2A is a well-known oncoprotein whose expression is elevated in multiple human solid tumor types. However, its role in renal cell carcinoma (RCC) development is poorly understood.
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibitors were shown to benefit immunosuppressive regulatory T-cell (Treg) expansion, this might suppress antitumor immune responses. Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.
In patients with previously untreated advanced renal cell carcinoma (RCC) whose tumors were positive for the PD-L1 checkpoint, a combination of the checkpoint inhibitor avelumab and the tyrosine kinase inhibitor (TKI) axitinib increased the median PFS from 8.4 months to 13.8 months when compared with the TKI sunitinib (HR 0.69; P=0.0001).
MDACC 2018: Systemic Therapy for Metastatic Non-Clear Cell Histology Patients: What Works and What Doesnât?
Our 2017 YIA winner Pavlos Msaouel is doing great work in kidney cancer research. In this article, he explains chemotherapy vs. targeted therapies.
MDACC 2018: Debate: Is There Still a Role for Cytoreductive Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma?
Dr. Jose Karam explains the role of cytoreductive nephrectomies when patients have metastatic kidney cancer.
Dr. Msaouel discusses the best treatment options after failure of immune checkpoint inhibition.
|Powered by NeonCRM|